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Nanotechnology has been an ever-growing ﬁeld since the discovery of carbon fullerenes, and is being
assimilated progressively into a variety of other disciplines including medical science. The association
with neurosurgery had initially been less well characterized compared to other organ systems, but has
recently offered promising future potential for a wide range of utilities including new therapeutic options
for Glioblastoma Multiforme, neurprotection against oxidative stress, nerve nanorepair, nanodiagnosis of
Alzheimer’s disease, nanoimaging with nanoparticles and quantum dots, nanomanipulation of CNS with
surgical nanobots, and nanoneuromodulation with nanoﬁbres & nanowires. This article examines such
potentials as well as others, of the utility of nanotechnology in Neurosurgery.
 2011 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction to nanotechnology
Nanotechnology involves scales that can be characterized to an
order of 107e109 m. In biological terms, this would reﬂect the
range of sizes of viral particles, to the size of the smallest bacterium
belonging to theMycoplasma genus. This term should not, however,
be limited to mere particles of that order, or their visualization,
because it refers to a conglomerate of various disciplines and
subspecialties amongst physics, chemistry and biology that is
involved in design, synthesis, characterization and applications of
devices that can be measured at nanometer scale.1
This term was initially coined by Norio Taniguchi in 1974,
a professor at Tokyo Science University,2 and later was popularized
by Dr. Kim Eric Drexler, both of whom agreed, although unknow-
ingly, upon nanotechnology as processing, separation, consolida-
tion and deformation of materials by one atom or by one molecule.tan. Tel.: þ12169259648, þ92
ciates Ltd. Published by Elsevier LtThe idea is however unique to Richard Feynman’s famous talk in
1959: “There’s plenty of room at the bottom”, in which he envi-
sioned the development of nanomachines able to build other
nanomachines with atom-by-atom control.3
This is currently being managed by two peculiar techniques
designated as “topedown” and “bottomeup”. The former begins
with using a macroscopic material as a prototype and introducing
small-scaledetails in it, suchasutilized in creating integrated circuits
within silicon wafers in the semiconductor industry.1 The latter
begins by customizing molecules that later assemble and organize
themselves into higher order structures.4 As an example, nanoscale
electrode junctions have been created by using speciﬁc oligonucle-
otide sequences that direct the assembly of electrical circuits con-
taining 20 and 30 nm diameter DNA-modiﬁed nanoparticles.5
This article would explore the various avenues being exploited
by researchers in integrating Nanotechnology speciﬁcally with
applications in Neurosurgery. These include, but are not limited to:
1. Background of nanoparticles and blood brain barrier
2. Therapeutic modalities in Glioblastoma Multiforme, the results
of which have been extensively published across the journalsd. All rights reserved.
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4. Neuroprotection against oxidative stress with fullerenols
5. Nanoimaging and Nanodiagnostic modalities with iron oxide
nanoparticles and quantum dots
6. Nanoneuromodulation with nanoﬁbres and nanowires for
monitoring neuronal electrical activity and stimulation
7. Nanorepair of central and peripheral nerves2. Blood brain barrier and nanoparticles
The blood-brain-barrier is a highly impermeable barrier formed
by the endothelial cells in the central nervous system through tight
junctions that are primarily induced by astrocytes.6 Although cir-
cumventricular organs such as pineal gland and area postrema are
alienated to this barrier allowing secretion of melatonin into blood
and detection of emetic substances respectively, the relatively strict
protection afforded by the rest of the brain serves to exclude trans-
membrane transport of a majority of molecules, especially drugs.
Both lipophilic properties and a molecular size of <400e600 Da
threshold are important properties in determining the relative ease
by which transfer occurs across the blood brain barrier.7 For
molecules not satisfying either category, various transporters
unique for amino acids, peptides, hexoses etc, exist for their inﬂux.8
Despite these allowances, the blood brain barrier continues to
hinder development of drugs for the central nervous system and in
an estimate, the global. CNS pharmaceutical market must grow by
>500% to be comparable to the global market for cardiovascular
drugs.9 Another analysis has shown that CNS drugs constitute only
12% of the library of drugs that exists, and a meagre 1% drugs have
indications for non-affective CNS disorders.10 This problem is
further compounded by the presence of active efﬂux transporters
that includes P-glycoprotein and other members of the ATP-
binding cassettes. This is illustrated by the non-nucleoside
reverse transcriptase inhibitor Azidothymidine whose active
efﬂux transporter, although hasn’t yet been characterized at the
molecular level, also exhibits properties of efﬂux for Didanosine.11
While other methods have been attempted to circumvent the
BBB such as by direct intraventricular infusions of nerve growth
factor in patients with Alzheimer’s disease,12 nanoparticles offer
a bigger yet better promise of more efﬁcient drug delivery and
alleviated toxicities. These are polymers of alkylcyanoacrylates that
can disperse efﬁciently in an acidiﬁed aqueous medium with the
addition of surfactant. They can range in size from 1 to 3000 nm
that can incorporate drugs either during the polymerization
process, or adsorption to preformed nanoparticles.13 These nano-
particles mask the limitations imposed by the BBB on drug delivery
and possibly slow drug release from CNS resulting in decreased
peripheral drug toxicities.14 The manufacturing process offers
versatility in achieving different sizes of the nanoparticle through
controlling the temperature, pH of the solution, stirring rate,
acidifying agent and type of electrolyte.15 The size of the nano-
particle is likely to affect the transport of nanoparticles, often in
conjunction with other parameters such as temperature. In an
experiment, it has been demonstrated that transport of smaller
particle sizes of the order of 100 nm in comparison to 400 nm size,
is especially augmented by a temperature of 42 C compared to
a temperature of 34 C.16
Nanoparticles can be loaded with many different substances
such as contrast materials, drugs, dyes, and photosensitizers
through adsorption, encapsulation or covalent linkage depending
upon the properties established during the manufacturing process.
Efﬁcient delivery can be achieved through attachment of speciﬁc
targeting modalities such as monoclonal antibodies, and the
stability can be enhanced through attachment of Poly-ethyleneglycol to reduce the half-life and clearance. These nanoparticles
behave as macromolecules and are retained within the tumour
through Enhanced permeability and retention effect (EPR)17 even
after their serum levels fall. These particles effectively isolate the
materials in their core from the surrounding environment in order
to reduce systemic effects and removal of material, such as
decreasing systemic toxicities of chemotherapeutic drugs through
encapsulation into nanoparticles.
3. Nanotherapeutic modalities in glioblastoma multiforme
3.1. Chemotherapy
GlioblastomaMultiforme is themost prevalent andmalignant of
all adult brain tumours. This tumour is invariably lethal with
a median survival rate of an estimated 11.6 months.18 Long term
survival is also associated with this tumour, estimated at 5% (22
patients) for beyond 5 years for patients diagnosed with primary
supratentorial glioblastoma multiforme, with 20 patients having
a subtotal resection, and 2with a gross total resection.19 The current
treatment is with maximal surgical resection and adjuvant radia-
tion therapy and chemotherapy with temozolomide.20 Resection
however is not associated with strong survival signiﬁcance, with
a median age of survival being 13 months for resection greater than
98% and survival less than 8.8 months for resection less than 98%.21
Interstitial chemotherapy with carmustine also only improves the
median survival of 11.6 months by 2 months only.19 These obser-
vations reﬂect the difﬁculties experienced in adequately treating
this tumour. The potential therapeutic options utilizing the prin-
ciples of nanotechnology have been explored.
Glioblastoma Multiforme has been shown upregulate Low
Density Lipoprotein receptors. This has given way for the
construction of nano-LDL particles by using a synthetic peptide
with the lipid binding domain and the LDL-receptor binding
domain of Apo-B100 and combining them with lecithin and cho-
lesteryl oleate. After tagging themwith a ﬂuorescent marker, it was
demonstrated that these synthetic particles are taken up by the
tumour.22 It has further been demonstrated that these particles can
be tagged with lipophilic drugs and are made capable of tumour
cytotoxicity. Pacletaxel Oleate has been used in this manner and
when used together with suramin (an inhibitor of LDL receptor),
tumour cell survival improves.23 Similarly HDL particles have been
constructed with incorporated Paclitaxel and shown to have
superior cytotoxicity and 5e20 times lower half maximal inhibitory
concentrations than free drugs against cell lines other than Glio-
blastoma Multiforme.24 LDL receptors have also been shown to be
upregulated on Tenon Capsule’s ﬁbroblast after exposure to
Transforming Growth Factor-fÒ. This is hoped to become a focus for
targetted drug therapy in an attempt to control excessive scarring
during conjunctival healing.25
Apart from the LDL receptor, Interleukin-13 receptor has also
been demonstrated to be upregulated on Glioblastoma Multiforme
cells and this fact has been exploited by using a mutated Pseudo-
monas IL-13 cytotoxin that has been shown to be potent at killing
the tumour cells.26 Modiﬁed fullerenes have been conjugated with
an IL-13 peptide and demonstrated to show speciﬁcity for the
tumour cells, and are purported to be utilized as a drug delivery
system in near future.27 Further selective targeting is also demon-
strated by boron nitride nanotubes that have been demonstrated to
be speciﬁcally taken up by the tumour cells.28 From these results, it
can only be hoped that these modalities can offer improve survival
rates and durations for patients suffering from this tumour.
Fujita et al29 have investigated the use of two different mono-
clonal antibodies, an antimouse transferring receptor antibody and
a mouse autoimmune anti-nucleosome antibody 2C5, by tagging
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antisense oligonucleotides to vascular protein laminin-8. This
conﬁguration was intravenously administered into rat models
bearing glioma. Fluorescence imaging after 24 h demonstrated
a signiﬁcantly higher tumour accumulation using a platform with
two monoclonal antibodies instead of a single one. The authors
argue that this tandem conﬁguration enhances tumour targeting
potential and efﬁcacy. From these results, it can only be hoped that
these modalities can offer improve survival rates and durations for
patients suffering from this tumour.
3.2. Gene therapy
Gene therapy involves incorporation of genes into the tumour
genome to produce the desired apoptotic effect. Both viral vectors
and liposomes have been utilized to deliver the exogenous genes to
tumour cells. Lu et al30 have investigated the use of non-viral vector
cationic albumin-conjugated pegylated nanoparticles (CBSA-NP)
integrated with the plasmid pORF-hTRAIL (pDNA). The authors
intravenously administered the resulting CBSA-NP-hTRAIL to BALB/
c mice bearing i.c. C6 gliomas and the released pDNAwas present in
the nucleus after 6 h and induced apoptosis 48 h after transfection.
They inhibited tumour growth and prolonged survival when
compared with the blank nanoparticle NP-hTRAIL in mice. This
shows the promising utility of CBSA-NP-hTRAIL for noninvasive
gene therapy of gliomas.
3.3. Thermotherapy
The effect of hyperthermia on solid glioma tissues implanted
subcutaneously in rat models has been investigated. Magnetic
cationic liposomes were injected into the solid tumours and sub-
jected to an alternating magnetic ﬁeld. Rats were divided into four
groups with the ﬁrst receiving no irradiation, second receiving
irradiation for 30 min, third for 60 min and the fourth with 90 min.
Within the last group, tumour regression was observed in 87.5% of
the rats and within the third group, it regressed in 60% of rats.
Histological examination showed least MCL dispersion in the ﬁrst
group and the most within the last group, and this factor was found
to be signiﬁcant for tumour regression. Importantly no severe side
effects were observed.31
Data from animal studies have prompted the investigation of
thermotherapy in clinical trials. Maier-Hauff et al32 injected ami-
nosilane coated iron oxide nanoparticles in 14 patients with
recurrent glioblastoma multiforme. The patients were subse-
quently exposed to alternating magnetic ﬁeld to cause particle
heating. Patients were given 4e10 thermotherapy treatments after
instillation of magnetic ﬂuid and single fractions of a radiotherapy
series. Although effects were not remarkable, the patients experi-
enced negligible side effects with the therapy leading to the
conclusion that thermotherapy can be safely applied on patients
with GBM.
3.4. Photodynamic therapy
The idea behind photodynamic therapy (PDT) revolves around
the use of a photosensitizer which, after activation with light,
would enable cellular oxygen to generate reactive species causing
cell toxicity.33 This was investigated by Reddy et al34 where the
researchers developed multifunctional polymeric nanoparticle
with a tumour vasculature targeting F3 peptide and encapsulated
PDT and imaging agents. These were administered intravenously to
rat models bearing 9L gliomas and signiﬁcant MRI contrast
enhancement was achieved. This was compared with rat models
receiving systemic photofrin or nontargeted nanoparticles. Thesurvival was greater than 6 months in two out of ﬁve rats receiving
targeted nanoparticles with a mean of 33 days whereas survival
was only 8.5 days in rats receiving control treatment.
Gold nanoshells have also been investigated in the photo-
thermal treatment of glioma through macrophage-mediated
delivery.35 Nanoshells have a dielectric core that is coated with
a gold layer which can absorb Near-infrared light (NIR) and
convert it into heat. Macrophages have a natural ability of
traversing the Blood Brain Barrier and when loaded with anti-
tumour agents, can serve as vectors for delivery to tumours and
surrounding tissues. The authors used empty or nanoshell loaded
macrophages and investigated the effects of exposure to NIR
laser. Their results demonstrate the avid uptake of nanoshells by
macrophages and inﬁltration into the glioma spheroids. The NIR
laser exposure resulted in complete growth inhibition compared
to controls.4. Nanomanipulation and surgical nanorobots
Nanomanipulation is purported to represent what might be
termed as “surgery at the nano level”.36 It involves the use of
nanodevices such as nanorobots to be introduced into the
vascular system or body cavities, programmed and controlled
remotely by the surgeon, and perform various diagnostic and
therapeutic functions in a very precise and minimally invasive
manner leading to faster recovery, while communicating with the
on-site surgeon through signals. Various applications have already
been investigated. A rapidly vibrating (100 Hz) micropipette with
<1 micron tip has been used to dissect the apical dendrites of rat
hippocampal CA1 pyramidal cells which result in complete
disconnection of dendrites and maintained cell viability.37 Axot-
omy performed in roundword neurons using femtosecond laser
surgery resulted in complete regeneration.38 Laser axotomy was
also performed on D-type axons of C. Elegans with femtosecond
laser. The researchers also employed confocal ﬂuorescence
imaging and laser scanning brightﬁeld for real-time imaging
which was used to study the development of incision, presence of
any possible collateral damage and improve the technique. The
authors argue that the potential of this imaging to be used in
nanosurgery and axon regeneration is vast.39 Other surgical
nanorobots outﬁtted with operating instruments and capable of
precise mobility for microvascular surgery, organ transplants,
molecular repairs on cells, and eliminating cancerous cells have
also been envisioned.405. Neuroprotection with nanotechnology
5.1. Fullerenols
The brain tissue is especially sensitive to ischaemia which can
be precipitated by a variety of systemic conditions such as hae-
morrhage, cardiovascular compromise or stroke. Fullerenes are
molecules composed of large 3-dimensional arrays of evenly
spaced carbon atoms. Spherical fullerenes are called buckyballs
and cylindrical ones are designated cabon nanotubes. The ﬁrst
fullerene to be discovered was buckministerfullerene, in 1985 by
the three eventual Nobel Laureates Robert Curl, Harold Kroto and
Richard Smalley. These molecules have been shown to possess
antioxidant and free-radical scavenger properties that can
reduce NMDA-, AMPA-, and glutamate induced excitotoxic and
apoptotic cell death.41,42 The mechanism is a selective inhibition
of glutamate channels resulting in decreased Calcium inﬂux and
thereby avoidance of excitotoxic and apoptotic effects on the
neurons.42
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HIV Encephalopathy and AIDSeDementia complex are some of
the neurological complications associated with the primary HIV
infection alongside vacuolar myopathy, peripheral neuropathies
and polymyositis. The usual corresponding CD4þ lymphocyte
count is below 200/fÝl although with the advent of highly active
anti-retroviral therapy (HAART), the delay towards a gradual
reduction in lymphocyte count manifests a mild symptom spec-
trum of encephalopathy.43 Even though the encephalopathy
complex is still continually being reported, evidence suggests that
aggressive early HAART treatment to prevent severe immunosup-
pression may prevent these disorders.44 Other studies suggest
improvement in neuropsychological testing and reversal of
neurological symptoms especially motor performance, with HAART
initiation compared to patients without HAART who steadily
worsen.45 Therefore aggressive early HAART forms the current
standard of care, however most of these drugs have poor CNS
penetrance but whether this has any clinical signiﬁcant remains
unknown.46
One of the proposed mechanisms for HIV induced neurotoxicity
is neuronal apoptosis, through activation of glial cells and macro-
phages that may not necessarily be directly related to HIV infection,
causing oxidative stress. This is especially strongly predominant in
basal ganglia and correlates well with HIV Encephalitis.47 Macro-
phages are the direct seat of HIV infection and productivity.48
Therefore in-vitro studies into direct macrophage targeting using
colloid nanoparticles and human serum albumin with size
<200 nm labelled with Azidothymidine have shown high intake of
these nanoparticles and promising results (29).49 Furthermore the
HIV-infected macrophages have demonstrated a higher intake of
azidothymidine coated nanoparticles than do non-infected
macrophages.49 The reverse-protease inhibitor, Saquinavir, has
demonstrated a 10 times increase in its efﬁcacy in its antiviral effect
when compared to an aqueous solution of the drug.50 Systemic
infection by HIV has also been targeted with modiﬁed nano-
particles that display ligands for the HIV-speciﬁc receptors CD4 and
CCR5 on macrophages, especially in lymph nodes.51
6. Nanoimaging and nanodiagnostic modalities
6.1. Alzheimer’s disease
Alzheimer’s disease is the most common cause of dementia in
the elderly resulting in signiﬁcant debility. The accumulation of
Beta-Amyloid plaques has been linked to triggering neuronal
degeneration by altering the Calcium balance of the neurons.52
Another theory focuses on deﬁciency of acetylcholine in the brain
and is linked to destruction especially of acetylcholine containing
neurons in the basal nucleus of Meynert. This is the subject of
pharmacological management of the disease using acetylcholin-
esterase inhibitors such as galantamine and rivastigmine. Mem-
antine, a non-competitive NMDA receptor antagonist is also used to
inhibit over-excitation resulting from glutamate and consequent
cell death. These medications form the current symptomatic
treatment regimen for Alzheimer’s. The NINCDS-ADRDA criteria is
used to diagnose Alzheimer’s but considerable confusion can exist
with other entities such as Frontotemporal dementia.53 This criteria
is now being revised in lieu of availability of several distinctive and
reliable criteria of biomarkers available in CSF.54
These biomarkers include the presence of tau proteins and beta-
amyloid proteins in the cerebrospinal ﬂuids. Detection for phos-
phorylated tau181P in the CSF resulted in a sensitivity of 94e100%
when compared to histopathological conﬁrmation on autopsy.55
Recently Amyloid-Beta-derived diffusible ligands (ADDLs) havebeen proposed as the neurotoxins whose presence correlates
directly with memory loss associated with Alzheimer’s disease.56
This circumvents the reliance on correlation between presence of
Amyloid plaques in the brain which have not been adequately
correlated with symptomatology of Alzheimer’s disease.56 The
scope of nanotechnology has allowed development of ultra-
sensitive bio-barcode assay to measure the concentration of these
ADDLs in CSF making it a potential diagnostic tool.57 This example
of a nanodiagnostic promises increased sensitivity, multiplexing
capabilities, and reduced cost for many diagnostic applications.58
6.2. Imaging by iron oxide nanoparticles
Ferumoxtran-10 is a dextran coated iron oxide nanoparticle that
has been used as a contrast adjunct to Magnetic Resonance Imaging
of brain for malignant tumours, as compared to the more tradi-
tional gadolinium-enhanced MRI scan.59 It has shown several
advantages over gadolinium, allowing for enhancement of those
regions of the tumour not visualized with gadolinium, and the
ferumoxtran-10 enhancing lesions have persistent increased T1
signal intensity for 2e5 days postoperatively. These ﬁndings have
the potential in assisting image-guided neurosurgery and improve
the diagnosis of lesions caused by multiple sclerosis, stroke etc.
Additionally ferumoxtran-10 is taken up by reactive cells in brain
allowing for histological examination of the tissue with simple iron
staining.
These iron-oxide nanoparticles have other potential applica-
tions. They have been shown to assist in determining the density of
the Tyrosine kinase Her-2/neu receptor by attaching to the cell
surface and being imaged by MR molecular imaging.60 Determi-
nation of this receptor positivity status of breast cancer has
signiﬁcant impact on the staging and treatment of the cancer.
Additionally they have been shown to document degree of
inﬂammation in the nephritic rat kidneys, on MR imaging.61
6.3. Intraoperative imaging through iron oxide nanoparticles
Achieving adequate resection of margins in brain tumour
surgery is a critical step that ultimately determines the outcome
and progression free survival.62 However this can be challenging
due to inability to accurately delineate the tumour margins and is
based on the subjective impression of the concerned neurosurgeon.
Residual tumour may still remain even after total resection of the
tumour.63 While intraoperative MRI is utilized to aid in resection of
the tumour margins, abnormalities around the resection area have
been observed postoperatively creating potential confusion
residual tumour and interpreted as treatment failure.64 Similarly
use of ﬂuorescent dyes to visualize tumour margins can result in
inability to concentrate an adequate amount speciﬁcally within the
tumour area. This has led to the development of Iron oxide nano-
particles that harbour the near-infrared ﬂuorescing molecule
(NIRF) Cy5.5 which was detected in a model of gliosarcoma with
green-ﬂuorescing protein-expressing 9L glioma cells. Sequestration
by microglia and optical and magnetic properties of the probe
enabled tumour margin detection by preoperative MRI imaging
and intra-operative optical imaging.65 Another group covalently
bound the iron oxide nanoparticles with polyethylene glycol,
subsequently functionalizing it with chlorotoxin and Cy5.5. Both
MRI and ﬂuorescence microscopy displayed signiﬁcant uptake of
the nanoparticles by the glioma cells.66
6.4. Quantum dots
These are alternatives to the Cy5.5 laden iron oxide nano-
particles that are made of semiconductor materials, ranging in size
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properties due to their tiny size, which is different from the bulk
material. The most signiﬁcant effect is emission of photons under
excitation that is perceived as light by eye. The emitted wavelength
depends on the size of the quantum dot rather than the material
used. This enables creating different size quantum dots that can
emit various wavelengths, including those within the range of
visible light, and beyond.67 Jackson et. al68 have investigated the
use of 705 nm emission Qdot ITK Amino(PEG) Quantum dots by
injecting into the tail veins of rats after intracranially implanting C6
gliosarcoma cell lines and sacriﬁcing the animals after 24 h. It was
noted that at low doses, the quantum dots were phagocytized by
the reticuloendothelial system and at higher doses, it was localized
by the microglia present within the gliosarcoma implantation and
optically outlining the tumour. The tumour was subsequently
excited with UV wavelengths and emitting a deep red ﬂuorescence.
While it requires the use of ﬂuorescence imaging and darkening the
operative ﬁeld, it may be possible to ﬁne-tune the quantum dots to
emit visible light.67
7. Nanoneuromodulation
7.1. Nanoﬁbre brain implants
Implants are commonly utilized in neurosurgery in electrically
stimulating of blocking neurons.69 They form a part of what is
known as “biomedical prosthesis” and have indications encom-
passing use in research in animal models to study behaviour70 or
use clinically as deep brain stimulation for treatment of clinical
depression, intractable pain and Parkinson’s disease.71
These brain implants are designated as foreign by the body and
consequently these probes become encapsulated due to a ﬁbrotic
response from the glial and immune cells resulting in device
failure.72 The use of carbon nanoﬁbres as neural prosthesis has
been demonstrated to achieve better results. Preparation of four
substrates, two with conventional diameters of greater than
100 nm and the other two with nanoscale diameters, and
implantation showed preferential adherence of astrocytes to
substrates of greater diameter. This evidenced decreased adhesion
of astrocytes to carbon nanoﬁbres and thereby limited glial tissue
expression on the ﬁbres.73 These Carbon nanoﬁbres have also been
doubled as microelectrodes for a retinal prosthesis with results
showing good biocompatibility.74
7.2. Nanowires
These are structures with diameters of only a few nanometres
and extended lengths. Typically the length to width ration is
extremely large making them effectively one-dimensional struc-
tures. These are futuristic compounds that would be used to link
together tiny components into extremely small circuits. These
nanowires are purported to have functions in monitoring brain
electrical activity without having to use a brain probe and violating
the brain parenchyma. Using platinum nanowires, researchers have
used blood vessels as the guiding pathway to determining the
electrical activity of neurons that are adjacent to the blood
vessels.75 These nanowires can both deliver electrical impulses as
well as receive. Because of the potential for targeting speciﬁc areas
of the brain, they can enable new treatment modalities for various
neurological diseases. Electrode stimulation has already been
shown to be of clinical beneﬁt to patients of Parkinson’s disease71
and this method of stimulation avoids the use of penetrating
brain implants which may result in scarring of the brain paren-
chyma. Another form of nanowires, polymer nanowires,75 has the
advantage of changing shape in response to electrical ﬁeldsallowing precise steering through the circulatory system of brain
towards the exact spot of interest. These also have the beneﬁt of
being 20e30 times smaller than the platinum ones and are
biodegradable, allowing for short-term use of brain implants.758. Nanorepair of nerves
Damage to nerves is a fairly common outcome of traumatic,
iatrogenic or infectious processes. There are various examples that
can illustrate nerve injuries encountered in clinical practice.
Brachial plexus injuries can occur in newborn infants during the
process of delivery with a frequency that varies between 0.01 and
0.15%.76 Cancer chemotherapy such as Cisplatin can damage the 8th
Cranial Nerve. Surgical procedures such as dacryocystorhinostomy
can also damage the peripherally placed ﬁbres of facial nerve in the
vicinity of medial canthal area causing abnormal eyelid closure
postoperatively.77 The success of natural reparative process
depends on whether the connective tissue layers around the nerve
are intact (which predicts best prognosis according to Seddon’s
classiﬁcation of nerve injury) or not.
Currently two modalities are being further developed to aid in
nerve recovery: microtechnology and nanotechnology.78 Both are
currently being explored in tandem to address two novel meth-
odologies of treating severe nerve injuries that typically cause
incomplete or non-existent functional recovery: microstructured
scaffolds to promote regeneration and direct repair by reconnecting
the severed axons. The former involves creating a tissue scaffold
using microtechnology with precisely altered surface chemistry by
nanotechnology, in order to provide a microenvironment favour-
able for the regeneration of the axon. The latter involves directly
attempting to acutely reconnect the severed axons using ultra-
microsurgical tools that would permit safe manipulation of the
individual axons without incurring damage.79 Recently in an
experiment on mammals with attempt to sever optic tracts and
using a self-assembling peptide nanoﬁbre scaffold to create
a permissible environment for axonal regeneration, adequate
functional return of vision has been reported using visual stimuli to
elicit speciﬁc behaviour patterns.80 In another experiment on dogs
with induced injury to thoracic sympathetic trunk and phrenic
nerves in order to elicit Horner’s syndrome and diaphragmatic
paralysis, the usefulness of chitosan nano/microﬁbre mesh tubes
(C-tubes) was well evidenced by improvement in Horner’s
syndrome and response of diaphragm to phrenic nerve
stimulation.819. Conclusion
Nanotechnology provides a futuristic portrayal of the destiny of
medicine and surgery. Although incorporation into neurosurgery
and neuroscience has been slow compared to other ﬁelds of
medicine, the experimental work has gained an explosive
momentum of late and has provided the realization of potential
beneﬁts in addressing various notorious conditions of the nervous
system encompassing malignant tumours, nerve injuries, drug
delivery mechanisms, novel diagnostic and imaging methods,
neuroprotection and unique brain implants and use of exotic
compounds such as nanowires in treatment of various neurological
conditions such as Parkinson’s disease. With the advent and
popularity of minimally invasive surgeries and interventional
techniques, nanotechnology provides a future platform for further
development of neuroscience and neurosurgery along these lines
and warrants careful understanding and appreciation by every
physician of how medicine could be entirely transformed in near
future.
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